Equities analysts expect Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to report sales of $94.00 million for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Neurocrine Biosciences’ earnings. The business is scheduled to announce its next quarterly earnings report after the market closes on Tuesday, February 13th.
On average, analysts expect that Neurocrine Biosciences will report full-year sales of $94.00 million for the current year, with estimates ranging from $161.00 million to $161.11 million. For the next fiscal year, analysts forecast that the firm will post sales of $402.29 million per share, with estimates ranging from $295.19 million to $511.00 million. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Neurocrine Biosciences.
Several equities analysts recently issued reports on NBIX shares. Jefferies Group upped their target price on Neurocrine Biosciences to $105.00 and gave the company a “buy” rating in a research report on Friday, January 5th. BMO Capital Markets upped their target price on Neurocrine Biosciences from $83.00 to $109.00 and gave the company an “outperform” rating in a research report on Thursday, November 2nd. Oppenheimer set a $85.00 target price on Neurocrine Biosciences and gave the company a “buy” rating in a research report on Tuesday, December 12th. Needham & Company LLC reissued a “buy” rating and issued a $86.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. Finally, Leerink Swann reissued an “outperform” rating and issued a $83.00 target price (up from $72.00) on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. One equities research analyst has rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $82.31.
A number of large investors have recently bought and sold shares of the business. Sigma Planning Corp purchased a new stake in shares of Neurocrine Biosciences during the 4th quarter worth about $241,000. Swiss National Bank boosted its stake in shares of Neurocrine Biosciences by 2.0% during the 4th quarter. Swiss National Bank now owns 150,200 shares of the company’s stock worth $11,654,000 after acquiring an additional 2,900 shares in the last quarter. Lisanti Capital Growth LLC purchased a new stake in shares of Neurocrine Biosciences during the 4th quarter worth about $656,000. Daiwa Securities Group Inc. purchased a new stake in shares of Neurocrine Biosciences during the 4th quarter worth about $4,829,000. Finally, California Public Employees Retirement System boosted its stake in shares of Neurocrine Biosciences by 5.6% during the 4th quarter. California Public Employees Retirement System now owns 192,135 shares of the company’s stock worth $14,908,000 after acquiring an additional 10,235 shares in the last quarter.
Neurocrine Biosciences (NBIX) opened at $82.75 on Thursday. The stock has a market capitalization of $7,320.00, a price-to-earnings ratio of -37.27, a PEG ratio of 13.51 and a beta of 0.26. The company has a current ratio of 14.38, a quick ratio of 14.37 and a debt-to-equity ratio of 1.05. Neurocrine Biosciences has a 12-month low of $39.21 and a 12-month high of $91.82.
ILLEGAL ACTIVITY WARNING: “Neurocrine Biosciences, Inc. (NBIX) Expected to Announce Quarterly Sales of $94.00 Million” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2018/02/08/neurocrine-biosciences-inc-nbix-expected-to-announce-quarterly-sales-of-94-00-million.html.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.